Global Optic Nerve Disorders Treatment Market is valued at approximately USD 3.4 billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Optic Nerve Disorders can be defined as patterns of vision loss that are generally caused by developmental disorders or acquired disorders. Moreover, damage to an optic nerve or its pathways to the brain causes, loss of vision. There are different types of disorders that affect the optic nerve, including Coloboma of optic nerve, Glaucoma, Idiopathic intracranial hypertension, Neuromyelitis optica, Optic nerve atrophy, Optic nerve drusen, Optic nerve pit, Optic neuritis, Septo-optic dysplasia, and Toxic amblyopia (nutritional amblyopia) among others. The increasing incidence of glaucoma and growing number of aging populations are key factors driving the market growth.
The rising number of geriatric individuals is contributing towards the growth of the Global Optic Nerve Disorders Treatment Market. According to the World Bank Group, the world's old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050. Another important component driving space is growing incidences of glaucoma. For instance - World Glaucoma Association - in 2020, globally around 79.6 million individuals were affected by glaucoma in 2020, and as per projections, this number is likely to increase to 111.8 million individuals in 2040. Also, growing expansion of pharmaceutical and biotechnology industries and rising healthcare spending would create a lucrative growth prospectus for the market over the forecast period. However, the high cost of Optic Nerve Disorders Treatment stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Optic Nerve Disorders Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to factors such as increase in healthcare spending by the governments of nations in these regions and rise in awareness about optic nerve disorders. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and presence of leading market players in the region.
Major market players included in this report are:
- Santen Pharmaceutical Co. Limited
- Allergan Plc.
- Novartis AG
- Pfizer, Inc.
- Bausch Health Companies, Inc.
- Aerie Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.,
- Bionure Farma, S.L.
- Mallinckrodt Pharmaceuticals
- AdvaCarePharma
Recent Developments in the Market:
- In August 2020, The FDA approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord.
Global Optic Nerve Disorders Treatment Market Report Scope:
- Historical Data: 2019-2020-2021
- Base Year for Estimation: 2021
- Forecast period: 2022-2029
- Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered: Treatment Type, Indication, End-User, Region
- Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
- Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.
By Treatment Type
By Indication
- Optic Neuritis
- Glaucoma
- Congenital Optic Atrophy
- Optic Neuropathy
- Others
By End-User
- Hospitals
- Clinics
- Ambulatory Surgery Centers
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Rest of the World
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
- 1.2.1. Optic Nerve Disorders Treatment Market, by Region, 2019-2029 (USD Billion)
- 1.2.2. Optic Nerve Disorders Treatment Market, by Treatment Type, 2019-2029 (USD Billion)
- 1.2.3. Optic Nerve Disorders Treatment Market, by Indication, 2019-2029 (USD Billion)
- 1.2.4. Optic Nerve Disorders Treatment Market, by End-User, 2019-2029 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Optic Nerve Disorders Treatment Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Optic Nerve Disorders Treatment Market Dynamics
- 3.1. Optic Nerve Disorders Treatment Market Impact Analysis (2019-2029)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing incidence of glaucoma
- 3.1.1.2. Growing number of aging populations
- 3.1.2. Market Challenges
- 3.1.2.1. High cost associated with optic nerve disorders treatment
- 3.1.3. Market Opportunities
- 3.1.3.1. Growing expansion of pharmaceutical and biotechnology industries
- 3.1.3.2. Rising healthcare spending
Chapter 4. Global Optic Nerve Disorders Treatment Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. Industry Experts Prospective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1. Assessment of the overall impact of COVID-19 on the industry
- 5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Optic Nerve Disorders Treatment Market, by Treatment Type
- 6.1. Market Snapshot
- 6.2. Global Optic Nerve Disorders Treatment Market by Treatment Type, Performance - Potential Analysis
- 6.3. Global Optic Nerve Disorders Treatment Market Estimates & Forecasts by Treatment Type 2019-2029 (USD Billion)
- 6.4. Optic Nerve Disorders Treatment Market, Sub Segment Analysis
- 6.4.1. Pharmacological Treatment
- 6.4.2. Surgery
Chapter 7. Global Optic Nerve Disorders Treatment Market, by Indication
- 7.1. Market Snapshot
- 7.2. Global Optic Nerve Disorders Treatment Market by Indication, Performance - Potential Analysis
- 7.3. Global Optic Nerve Disorders Treatment Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
- 7.4. Optic Nerve Disorders Treatment Market, Sub Segment Analysis
- 7.4.1. Optic Neuritis
- 7.4.2. Glaucoma
- 7.4.3. Congenital Optic Atrophy
- 7.4.4. Optic Neuropathy
- 7.4.5. Others
Chapter 8. Global Optic Nerve Disorders Treatment Market, by End-User
- 8.1. Market Snapshot
- 8.2. Global Optic Nerve Disorders Treatment Market by End-User, Performance - Potential Analysis
- 8.3. Global Optic Nerve Disorders Treatment Market Estimates & Forecasts by End-User 2019-2029 (USD Billion)
- 8.4. Optic Nerve Disorders Treatment Market, Sub Segment Analysis
- 8.4.1. Hospitals
- 8.4.2. Clinics
- 8.4.3. Ambulatory Surgery Centers
- 8.4.4. Others
Chapter 9. Global Optic Nerve Disorders Treatment Market, Regional Analysis
- 9.1. Optic Nerve Disorders Treatment Market, Regional Market Snapshot
- 9.2. North America Optic Nerve Disorders Treatment Market
- 9.2.1. U.S. Optic Nerve Disorders Treatment Market
- 9.2.1.1. Treatment Type breakdown estimates & forecasts, 2019-2029
- 9.2.1.2. Indication breakdown estimates & forecasts, 2019-2029
- 9.2.1.3. End-User breakdown estimates & forecasts, 2019-2029
- 9.2.2. Canada Optic Nerve Disorders Treatment Market
- 9.3. Europe Optic Nerve Disorders Treatment Market Snapshot
- 9.3.1. U.K. Optic Nerve Disorders Treatment Market
- 9.3.2. Germany Optic Nerve Disorders Treatment Market
- 9.3.3. France Optic Nerve Disorders Treatment Market
- 9.3.4. Spain Optic Nerve Disorders Treatment Market
- 9.3.5. Italy Optic Nerve Disorders Treatment Market
- 9.3.6. Rest of Europe Optic Nerve Disorders Treatment Market
- 9.4. Asia-Pacific Optic Nerve Disorders Treatment Market Snapshot
- 9.4.1. China Optic Nerve Disorders Treatment Market
- 9.4.2. India Optic Nerve Disorders Treatment Market
- 9.4.3. Japan Optic Nerve Disorders Treatment Market
- 9.4.4. Australia Optic Nerve Disorders Treatment Market
- 9.4.5. South Korea Optic Nerve Disorders Treatment Market
- 9.4.6. Rest of Asia Pacific Optic Nerve Disorders Treatment Market
- 9.5. Latin America Optic Nerve Disorders Treatment Market Snapshot
- 9.5.1. Brazil Optic Nerve Disorders Treatment Market
- 9.5.2. Mexico Optic Nerve Disorders Treatment Market
- 9.5.3. Rest of Latin America Optic Nerve Disorders Treatment Market
- 9.6. Rest of The World Optic Nerve Disorders Treatment Market
Chapter 10. Competitive Intelligence
- 10.1. Top Market Strategies
- 10.2. Company Profiles
- 10.2.1. Santen Pharmaceuticals Co. Limited
- 10.2.1.1. Key Information
- 10.2.1.2. Overview
- 10.2.1.3. Financial (Subject to Data Availability)
- 10.2.1.4. Product Summary
- 10.2.1.5. Recent Developments
- 10.2.2. Allergan Plc.
- 10.2.3. Novartis AG
- 10.2.4. Pfizer, Inc.
- 10.2.5. Bausch Health Companies, Inc.
- 10.2.6. Aerie Pharmaceuticals, Inc.
- 10.2.7. Teva Pharmaceutical Industries Ltd.,
- 10.2.8. Bionure Farma, S.L.
- 10.2.9. Mallinckrodt Pharmaceuticals
- 10.2.10. AdvaCarePharma
Chapter 11. Research Process
- 11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes
- 11.3. Research Assumption